U.S. markets open in 6 hours 22 minutes

Wize Pharma, Inc. (WIZP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.1000+0.0500 (+4.76%)
At close: 3:16PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close1.0500
Open1.0600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.0200 - 1.1500
52 Week Range0.0600 - 1.4500
Volume95,416
Avg. Volume130,503
Market Cap36.358M
Beta (5Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-0.5510
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Wize Pharma's Takeover Offer for Cosmos Capital Declared Unconditional
    PR Newswire

    Wize Pharma's Takeover Offer for Cosmos Capital Declared Unconditional

    Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has declared its previously announced off-market takeover offer ("Offer") for all of the ordinary shares in Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia ("Cosmos"), free from all of the conditions set out in the Offer and, accordingly, the Offer has become unconditional. A formal notice of the unconditionality of the Offer, as required under section 650F of the Corporations Act 2001 (Australia), is attached as Annexure A below.

  • Wize Pharma Receives Bonus BioGroup Shares from Escrow and Additional Bonus BioGroup Shares Totaling $1.3 Million
    PR Newswire

    Wize Pharma Receives Bonus BioGroup Shares from Escrow and Additional Bonus BioGroup Shares Totaling $1.3 Million

    Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that, on December 29, 2020, it has completed the transactions contemplated by the previously reported Addendum to a Share Purchase Agreement, dated November 29, 2020 (the "Addendum"), with Bonus BioGroup Ltd., a biotechnology company applying proprietary, innovative technology to supply tissue-engineered viable bone grafts, whose shares are listed on the Tel Aviv Stock Exchange (TASE: BONS.TA).

  • Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
    PR Newswire

    Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement

    Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia, today announced that they have entered into a bid implementation agreement ("BIA"), whereby Wize has agreed to make an off-market takeover offer to acquire all of the outstanding shares of Cosmos, subject to satisfaction of various closing conditions set forth in the BIA, resulting in Cosmos becoming a wholly-owned subsidiary of Wize.